PRA Health Sciences is a contract research organization with headquarters in Raleigh, North Carolina, USA. The organization has worked on 100+ drugs marketed across several therapeutic areas and conducted the pivotal or supportive trials that led to U.S. Food and Drug Administration (FDA) and/or international regulatory approval of 50+ such drugs.
Video PRA Health Sciences
History
PRA was founded in 1976 as the Anti-Inflammatory Drug Study Group in Charlottesville, Virginia, USA. Renamed PRA in 1982, it established itself as a data-management Contract Research Organization (CRO). After a number of strategic decisions to enhance its service offerings, the company became PRA Health Sciences in June 2014, incorporating partnerships and acquisitions made throughout 2012 and 2013.
Key dates:
- 1976: Anti-Inflammatory Drug Study Group formed in Charlottesville, VA
- 1982: Company established as Pharmaceutical Research Associates Inc. (PRA), a Data Management Contract Research Organization (CRO)
- 1991: Services extended to Clinical Trial Management and Drug safety. First European office established
- 1996: Acquired by Carlyle Group and reached 333 employees
- 1997: Acquired IMTCI in Lenexa, Kansas, USA whose facility included a Phase I unit
- 1999: Acquired Valorum (UK) with Regulatory and Product Registration teams
- 2000: Acquired ARCAM, Paris, France. Reached 1,000 employee landmark
- 2001: Acquired by Genstar Capital
- 2002: Acquired Staticon in Madrid, Spain and CroMedica to increase CNS expertise and expand its global footprint
- 2004: IPO made PRA a publicly traded stock on NASDAQ. Acquired Valid-Trio, Moscow, Russia and ClinCare in Russia, Belgium
- 2005: Acquired GMG BioBusiness Limited in the UK and Regulatory/Clinical Consultants in the USA. Reached 2,500 employee landmark
- 2006: Acquired Sterling Synergy Systems in Mumbai, India and Pharma Bio research in The Netherlands which formed the basis for the group within PRA now known as Early Development Services
- 2007: Reacquired by Genstar Capital and returns to being privately held. Acquired Pharmacon in Berlin, Germany. Opened its 25th office and reached 3,300 employees
- 2008: Moves global HQ to Raleigh, North Carolina, USA
- 2010: Colin Shannon named CEO. Bioanalytical Lab in Lenexa, Kansas, USA opened
- 2011: Acquired Kinship Technologies in Chennai, India
- 2012: Entered into a joint venture with WuXi PharmaTech to offer a broad platform of services in China, Hong Kong and Macau. Opened facilities in Singapore, Utrecht, The Netherlands, Beijing, China and Belgrade, Serbia
- 2013: Reached 10,000 employee and 70 office landmark. Purchased by Kohlberg Kravis Roberts (KKR), one of the world's leading Private Equity firms. Acquired ClinStar, a CRO/logistics firm providing services in Russia and Eastern Europe and RPS which later became the Strategic Solutions division of the company. Later in Nov 2013 acquired CRI Lifetree, a specialized research organization focusing on the conduct and design of early stage, patient population studies
- 2014: Renamed PRA Health Sciences to fully incorporate the companies within the PRA family, (RPS, CRI Lifetree, ClinStar and WuXiPRA). Launched a new website experience. PRA floats on the Nasdaq Global Select Market on November 13, 2014 under the ticker symbol "PRAH"
- 2015: PRA opened a new bioanalytical laboratory in Assen, the Netherlands
- 2016: PRA is named Clinical Research Company of the Year at the PharmaTimes USA and International Clinical Researcher of the Year competitions. PRA acquired Nextrials, a San Francisco-based, eClinical software company.
- 2017: Acquired Symphony Healthcare Solutions [1]
Maps PRA Health Sciences
Contribution to clinical development
PRA Health Sciences (PRA) has worked to develop a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs.
PRA has participated in several Clinical Trials of note such as the Landmark Alzheimer's Prevention Clinical Trial, a collaborative effort involving the Banner Alzheimer's Institute (BAI); Genentech, a member of the Roche Group; the University of Antioquia in Colombia; and the National Institutes of Health (NIH).
PRA were instrumental in supporting Gilead Sciences, Inc. with an FDA Breakthrough Therapy designation for Sovaldi (Sofosbuvir), which was approved by the FDA in December 2013. In addition, it was given a Notice of Compliance by Health Canada in December 2013, and granted Marketing Authorization by the European Commission in January 2014. Treatment is leading to higher cure rates and shortened, simplified therapy regimens for many Hepatitis C patients.
The organization has completed its 20th first in human trial with biologics. The milestone is the culmination of 600 subjects enrolled in over eight years of first-in-human biologics trials, including directly into patient experience.
In late 2015 PRA announced a collaboration with Alliance for Multispecialty Research (AMR) in an effort to accelerate new vaccines to market.
Accolades
PRA Health Sciences was named "Best CRO in Asia" at the BioPharma Asia Industry Awards in 2013, 2015 and 2017.
In the 2016 PharmaTimes US Clinical Researcher of the Year competition it was named "Clinical Company of the Year", as well achieving awards in several other categories.
The organization was awarded "International Clinical Company of the Year" at the PharmaTimes International Clinical Researcher of the Year contest in 2014, 2015 and 2016. Several employees were also recognized in individual categories.
In March 2016, PRA was awarded a Top Workplaces accolade by Philly.com. In the same month the company was also recognized in the Vaccine Industry Excellence (ViE) Awards in the "Best Contract Research Organization", receiving a "highly commended" designation.
External links
- PRA Health Sciences website
References
Source of the article : Wikipedia
0 Comments